Algernon Pharmaceuticals Inc. C.AGN

The IPF and Chronic Cough study is now on the back burner.

[BlaineBorg]

SH: Moving into the rest of the year, what milestones should investors be keeping an eye out for?

CJM: I think milestone one is feedback from the FDA on our COVID story. Let's see what next steps. Milestone number two is the phase one DMT stroke study and that we're hoping to start in Q3 to Q4 of this year. We should have IPF and chronic cough data by the end of this year, and based on the feedback from the FDA, we will be filing a pre-IND for pancreatic cancer. We may be starting a Phase One study for that indication sooner than the Q1 of 2022. So we've got a number of milestones for investors to think about and watch as the as the news unfolds here.

Biopharma Co. Makes Major Headway Toward Clinical Trials for Treatment of Stroke | 2021-06-16 | Investing News | Stockhouse 

BB

[TheBearInTheWoods]

Yes it is unfortunate the time a bio company takes to get through the process of phase 1-2-3 and it's not tree. Phase 1 - 1.5 mil and 6 months to have a drug made Phase 2 - 3-6 mil and 6-9 month to have a higher quality drug made , Trial timeline based on size Phase 3 - 50 million and 6-9 months with a higher quality drug made, much longer study  Remember of course that only 30% of

[BlaineBorg]

Those are just random numbers. They don';t apply to any and all clinical trials. You need only review the Topline data news release. It shows a phase 3 for Ifenprodil could range anywhere from 450 patoents to 1900 patients. Surely the per patient cost for domething like Cancer would likely cost more than COVID-19 or the common cough.  Algernon Pharmaceuticals Announces Topline Data From

[BlaineBorg]

Oh...but for the COVID-19 story dragging itself out from one quarter to the next, what would be the story at Algernon Pharmaceuticals since the launch of the IPF and Chronic Cough study? I'll tell you what would be the story. A B S O L U T  E L Y nothing. The company is talking about a phase 1 cclinical trial that might start in Q4 2021 (but likely sometime thereafetr) and some data

[Pandora]

Pulled this off the website but I do not see any follow up. Anybody have any input? This looks like the only thing that may give some life in 2021   December 24, 2020 11:42 ET | Source: Algernon Pharmaceuticals   ... VANCOUVER, British Columbia, Dec. 24, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE

[BlaineBorg]

There was a fire in 1 hospital halfway around the world the following month that affected 75% of the data. Hence, further delays and a readout that finally came on the very last day of Q1 2021. Kinda hard top believe it's been almost 6 months (half a year) since the end of the COVID-19 trial. 

[Danorrn]

I just got spammed by stockhouse and the CEO trying to pump the company out of the basement. He actually made it sound worse.

[BlaineBorg]

It can't get any worse because they don't know when they will achieve full enrollment. The timeline is already costing us big-time while another bs pp is on the horizon. If he cant land some government handout money or a partnership deal asap then I'm of the belief the business model and/or trial designs are flawed. They are simply too small to ever get to statistical significance and

[TheBearInTheWoods]

Management raised plenty of money for their wages and business expenses, retail just didn't see Mackie doing what they did. Great job on management for taking a .03 stock to .58 and doing a raise at .35!  they will do the same with DMT but not for some time ..... 

[BlaineBorg]

What we saw was Mackie smacking the c-rap out of Algernon Pharmaceuticals with their analysis of the COVID-19 Phase II Topline data readout. If the CEO crawls back to them with another PP that would be yet another astonishingly unfortunate thing to witness. I mean Mackie sank Algernon's battleship! Warranted...maybe?! You lie with dogs you catch fleas, but maybe that was the underplay for the

[BlaineBorg]

This post has been removed in accordance with Community Policy

[TheBearInTheWoods]

I agree with your post about Mackie, but for one thing. The CEO is a snake oil salesman, no one wants in for phase II as the odds of success are 30.1%. It's a lottery ticket that takes time with a high rate of failure  https://www.bio.org/sites/default/files/legacy/bioorg/docs/Clinical%20Development%20Success%20Rates%202006-2015%20-%20BIO,%20Biomedtracker,%20Amplion%202016.pdf

[BlaineBorg]

You're missing a big piece of the equation which is the safety issues of new drugs. Ifenprodil is not a new drug.  "NP-120 (Ifenprodil – brand name Cerocal) was initially developed by Sanofi in the 1990s in the French and Japanese markets for the treatment of circulatory disorders. Although no longer available in France, the drug is highly genericized and still sold in Japan."